For Lexington’s UniQure, hemophilia gene therapy approval is a comeback story
When the U.S. Food and Drug Administration approved the first gene therapy for hemophilia B on Tuesday, it was a win not only for CSL Behring, which owns the rights to the drug, but for Lexington’s UniQure NV. UniQure (Nasdaq: QURE) originally developed the drug, now called Hemgenix, and licensed it to CSL back in 2021. […]